tirzepatide australia cost Diabetes Medicine Access 💊 Big update on diabetes treatment in 👇 💊 Mounjaro not added to PBS ⚠️ Price negotiations blocked listing 💰 remains up to $645/month 👨‍⚕️ Other PBS New pharmacological treatments for obesity:

Additionally, I had a consultation for weight management and his approach gave me great confidence in their program.... C.R

Brello emphasizes continuity of care through regular check-ins, dose adjustment protocols, and adverse event monitoringdistinct from one-off prescription services that lack longitudinal follow-up

Cagrilintide starts at Week 9 in the staggered approach

MCTs have a high satiety value, preventing overconsumption of food (Kinsella et al

Key Findings 1 Tirzepatide reduced major kidney events by 23% vs dulaglutide Events: 6.0% vs 7.6% HR 0.77 (95% CI 0.680.88), p=0.0002 The risk of the primary composite kidney outcomewas 23% lower with tirzepatide than with dulaglutide. 2 Benefits were consistent across CKD risk categories Lowtomoderate risk CKD: HR 0.70 Highrisk CKD: HR 0.79 3 Mechanistic drivers differed by CKD stage Lowtomoderate CKD: Less newonset macroalbuminuria Highrisk CKD: Slower eGFR decline This was primarily driven by a lower rate of new-onset persistent macroalbuminuria and a lower rate of eGFR decline. 4 eGFR decline was significantly slower with tirzepatide Overall difference: +0.29 mL/min/1.73 m per year Highrisk CKD: +0.93 mL/min/1.73 m per year 5 Albuminuria improved more with tirzepatide At 36 months, UACR reductions were greater across CKD categories